Glutamate uptake

被引:3690
作者
Danbolt, NC [1 ]
机构
[1] Univ Oslo, Inst Basic Med Sci, Dept Anat, N-0317 Oslo, Norway
关键词
D O I
10.1016/S0301-0082(00)00067-8
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Brain tissue has a remarkable ability to accumulate glutamate. This ability is due to glutamate transporter proteins present in the plasma membranes of both glial cells and neurons. The transporter proteins represent the only (significant) mechanism for removal of glutamate from the extracellular fluid and their importance for the long-term maintenance of low and non-toxic concentrations of glutamate is now well documented. In addition to this simple, but essential glutamate removal role, the glutamate transporters appear to have more sophisticated functions in the modulation of neurotransmission. They may modify the time course of synaptic events, the extent and pattern of activation and desensitization of receptors outside the synaptic cleft and at neighboring synapses (intersynaptic cross-talk). Further, the glutamate transporters provide glutamate for synthesis of e.g. GABA, glutathione and protein, and for energy production. They also play roles in peripheral organs and tissues (e.g. bone, heart, intestine, kidneys, pancreas and placenta). Glutamate uptake appears to be modulated on virtually all possible levels, i.e. DNA transcription, mRNA splicing and degradation, protein synthesis and targeting, and actual amino acid transport activity and associated ion channel activities. A variety of soluble compounds (e.g. glutamate, cytokines and growth factors) influence glutamate transporter expression and activities. Neither the normal functioning of glutamatergic synapses nor the pathogenesis of major neurological diseases (e.g. cerebral ischemia, hypoglycemia, amyotrophic lateral sclerosis, Alzheimer's disease, traumatic brain injury, epilepsy and schizophrenia) as well as non-neurological diseases (e.g. osteoporosis) can be properly understood unless more is learned about these transporter proteins. Like glutamate itself, glutamate transporters are somehow involved in almost all aspects of normal and abnormal brain activity. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1 / 105
页数:105
相关论文
共 1260 条
[121]   AMPA receptors: Molecular and functional diversity [J].
Borges, K ;
Dingledine, R .
GLUTAMATE SYNAPSE AS A THERAPEUTICAL TARGET: MOLECULAR ORGANIZATION AND PATHOLOGY OF THE GLUTAMATE SYNAPSE, 1998, 116 :153-170
[122]   Neurotransmitter transporters: Molecular biology, function, and regulation [J].
Borowsky, B ;
Hoffman, BJ .
INTERNATIONAL REVIEW OF NEUROBIOLOGY, VOL 38, 1995, 38 :139-199
[123]   THE GLIAL-CELL GLUTAMATE UPTAKE CARRIER COUNTERTRANSPORTS PH-CHANGING ANIONS [J].
BOUVIER, M ;
SZATKOWSKI, M ;
AMATO, A ;
ATTWELL, D .
NATURE, 1992, 360 (6403) :471-474
[124]   GLUTAMINE - MAJOR SUBSTRATE FOR NERVE-ENDINGS [J].
BRADFORD, HF ;
WARD, HK ;
THOMAS, AJ .
JOURNAL OF NEUROCHEMISTRY, 1978, 30 (06) :1453-1459
[125]   Interactions between AMPA receptors and intracellular proteins [J].
Braithwaite, SP ;
Meyer, G ;
Henley, JM .
NEUROPHARMACOLOGY, 2000, 39 (06) :919-930
[126]   DISTRIBUTION OF GLUTAMATE-LIKE IMMUNOREACTIVITY IN EXCITATORY HIPPOCAMPAL PATHWAYS - A SEMIQUANTITATIVE ELECTRON-MICROSCOPIC STUDY IN RATS [J].
BRAMHAM, CR ;
TORP, R ;
ZHANG, N ;
STORMMATHISEN, J ;
OTTERSEN, OP .
NEUROSCIENCE, 1990, 39 (02) :405-417
[127]   The increasing power of immunohistochemistry and immunocytochemistry [J].
Brandtzaeg, P .
JOURNAL OF IMMUNOLOGICAL METHODS, 1998, 216 (1-2) :49-67
[128]   Ligands for glutamate receptors:: Design and therapeutic prospects [J].
Bräuner-Osborne, H ;
Egebjerg, J ;
Nielsen, EO ;
Madsen, U ;
Krogsgaard-Larsen, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (14) :2609-2645
[129]   A new structural class of subtype-selective inhibitor of cloned excitatory amino acid transporter, EAAT2 [J].
Bräuner-Osborne, H ;
Hermit, MB ;
Nielsen, B ;
Krogsgaard-Larsen, P ;
Johansen, TN .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 406 (01) :41-44
[130]   Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases [J].
Breitkreutz, R ;
Babylon, A ;
Hack, V ;
Schuster, K ;
Tokus, M ;
Böhles, H ;
Hagmüller, E ;
Edler, L ;
Holm, E ;
Dröge, W .
BRITISH JOURNAL OF CANCER, 2000, 82 (02) :399-403